BUSM Researchers Identify Chemical Compounds That Halt Virus Replication - Could Lead To Development Of Broad Spectrum Antivirals For Deadly Viruses
Claire Marie Filone, PhD, postdoctoral researcher at BUSM and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), is the paper's first author and led this study under the leadership of John Connor, PhD, associate professor of microbiology at BUSM and the study's corresponding author. John Snyder, PhD, professor of chemistry at Boston University (BU) and researchers from the Center for Chemical Methodology and Library Development at BU (CMLD-BU) were collaborators on this study.
Viruses are small disease-causing agents (pathogens) that replicate inside the cells of living organisms. A group of viruses known as nonsegmented, negative sense (NNS) ribonucleic acid (RNA) viruses cause common illnesses such as rabies, mumps and measles. These pathogens also cause more serious deadly diseases, including Ebola, Hendra and Nipah. Currently, there are no approved and effective treatments against these viruses, which, according to data from the Centers for Disease Control and Prevention, are associated with mortality rates up to 90 percent following infection.
"Identifying broad-spectrum antivirals is an important step in developing successful therapies against these and other viruses," said Filone. The basic idea of a broad spectrum antiviral is similar to that of broad spectrum antibacterials in that they would allow one drug to serve as a common treatment for many different viral illnesses.
In this study, researchers identified a new chemical class of compounds that effectively blocked genetically diverse viruses from replicating by limiting RNA production by the virus in cell culture. These indoline alkaloid-type compounds inhibited a number of viruses from replicating, including Ebola.
"Because the production of viral RNA is the first step in successful replication, it appears that we have uncovered an Achilles heel to halt virus replication," said Filone. "These compounds represent probes of a central virus function and a potential drug target for the development of effective broad-spectrum antivirals for a range of human pathogens."
Research highlighted in this press release was funded in part by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) under grant award numbers RO1 AI1096159-01 and K22AI-064606 (PI: Connor).
Claire Marie Filone, Erin N. Hodges, Brian Honeyman, G. Guy Bushkin, Karla Boyd, Andrew Platt, Feng Ni, Kyle Strom, Lisa Hensley, John K. Snyder, John H. Connor, Identification of a Broad-Spectrum Inhibitor of Viral RNA Synthesis: Validation of a Prototype Virus-Based Approach Chemistry & Biology, Volume 20, Issue 3, 424-433, 21 March 2013, doi: 10.1016/j.chembiol.2013.02.011
Boston University School of Medicine (BUSM)
Visit our Infectious Diseases / Bacteria / Viruses category page for the latest news on this subject, or sign up to our newsletter to receive the latest updates on Infectious Diseases / Bacteria / Viruses.
Please use one of the following formats to cite this article in your essay, paper or report:
Boston University School of Medicine (BUSM). "BUSM Researchers Identify Chemical Compounds That Halt Virus Replication - Could Lead To Development Of Broad Spectrum Antivirals For Deadly Viruses." Medical News Today. MediLexicon, Intl., 25 Mar. 2013. Web.
6 May. 2016. <http://www.medicalnewstoday.com/releases/258111.php>
Boston University School of Medicine (BUSM). (2013, March 25). "BUSM Researchers Identify Chemical Compounds That Halt Virus Replication - Could Lead To Development Of Broad Spectrum Antivirals For Deadly Viruses." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.